Should the FDA be requiring a Risk Evaluation and Mitigation Strategy for mifepristone? - Ep 147

ACCP JOURNALS - Podcast tekijän mukaan ACCP JOURNALS

kokeile Podimo ilmaiseksi 60! päivän ajan

kokeile Podimo ilmaiseksi 60! päivän ajan

universumia joka on täynnä satoja podcasteja ja äänikirjoja, klikkaa tätä kokeillaksesi

 Sponsored

Explore the basis for and controversy surrounding the US Food and Drug Administration requiring a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. Full text of the manuscript is available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.2034.

Visit the podcast's native language site